MedTrace Logo

Debridement, Antibiotics and Implant Retention in Early Periprosthetic Joint Infection: A Retrospective Cohort Study

NCT02087020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2014-03-14

No results posted yet for this study

Summary

Introduction: Periprosthetic joint infection (PJI) is a common cause for reoperation after knee and hip arthroplasty surgery. Debridement, antibiotics and implant retention (DAIR) is recommended in early infections (\< 4 weeks) and stable implants. Aims: To define the success rate of DAIR in early infections and to identify predictors for success. Material and methods: In a retrospective cohort study we included patients with hip- or knee arthroplasties reoperated for an early PJI at Danderyd Hospital 2007-2012. Logistic regression analysis was used to identify risk factors affecting success rate. Primary outcome variable was the success of the DAIR treatment. Secondary outcome variable vas risk factors for treatment failure.

Conditions

  • Direct Infection of Hip- and Knee Arthroplasty

Interventions

PROCEDURE

Debridement, antibiotics and implant retention

DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.

Sponsors & Collaborators

  • Danderyd Hospital

    lead OTHER

Principal Investigators

  • Olof G Skoldenberg, MD,PhD · Orthopaedic department, Danderyds hospital

  • Sebastian S Mukka, MD · Orthopaedic department, Danderyds hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02087020 on ClinicalTrials.gov